In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 7, 2011, Pages 398-407

  Luo, Jiang Ping ^a   Vashishtha, Sarvesh C ^a   Hawes, Edward M ^a   McKay, Gordon ^a,b   Midha, Kamal K ^a,b   Fang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Pharmalytics Inc   (Canada)

Author keywords

cytochrome P450; human; in vitro; loxapine; metabolism

Indexed keywords

7 HYDROXYLOXAPINE; 8 HYDROXYLOXAPINE; AMOXAPINE; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIMETHYLANILINE MONOOXYGENASE; KETOCONAZOLE; LOXAPINE; LOXAPINE N OXIDE; QUINIDINE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; LIVER MICROSOME; PHENOTYPE; PROTEIN EXPRESSION;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LOXAPINE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION;

EID: 80053186548     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.768     Document Type: Article

References (19)

1. Simpson GM, Cooper TB, Lee JH, Young MA,. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology 1978; 56: 225-232. (Pubitemid 8287712)
2. Glazer WM,. Does loxapine have 'atypical' properties? Clinical evidence. J Clin Psychiary 1999; 60 (suppl 10): 42-46. (Pubitemid 29237174)
3. Cooper TB, Dugal R, Bertrand MJ,. Determination of loxapine in human plasma and urine and identification of three urinary metabolites. Xenobiotica 1979; 9: 405-415.
4. Dugas JE, Weber SS,. Amoxapine. Drug Intell Clin Pharm 1982; 16: 199-204.
5. Cooper TB, Kelly RG,. GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine. J Pharm Sci 1979; 68: 216-219. (Pubitemid 9117129)
6. Coupet J, Rauh CE, Szues-Myers VA, Yunger LM,. 2-Chloro-11-(4-methyl-1- piperazinyl) dibenz[b,f][1,4]oxazepine (Amoxapine), an antidepressant with antipsychotic properties-a possible role for 7-hydroxyamoxapine. Biochem Pharmacol 1979; 28: 2514-2515. (Pubitemid 10240747)
7. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylates metabolites. Eur J Pharmacol 1979; 55: 215-218. (Pubitemid 9215642)
8. Singh AN, Barlas CS, Franks P,. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT-2 receptor subtypes. J Psychiatry Neurosci 1996; 21: 29-35. (Pubitemid 26045231)
9. Kapur S, Zipursly R, Remington G,. Evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997; 154: 1524-1529.
10. Trichard C, Paillere-Martinot ML, Attar-Levy D,. Binding of antipsychotic drugs to cortical 5HT2A receptors: a PET study of chlorpromazine, clozapine and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155: 505-508. (Pubitemid 28207446)
11. Stahl SM,. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999; 60 (suppl 10): 31-41. (Pubitemid 29237173)
12. Rosholm JU, Hallas J, Gram LF,. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in outpatients-A prescription database study. Br J Clin Pharmacol 1994; 37: 533-538. (Pubitemid 24197145)
13. Midha KK, Hubbard JW, McKay G, Hawes EM, Hsia D,. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 1993; 31: 177-183. (Pubitemid 23108060)
14. Fang J, Coutts RT, McKenna KF, Baker GB,. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 592-599. (Pubitemid 28518324)
15. Ereshefsky L, Riesenman C, Lam YWF,. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996; 57 (suppl 8): 17-24.
16. Guttendorf RJ, Wedlund PJ,. Genetic aspects of drug disposition and therapeutics. Br J Clin Pharmacol 1992; 32: 107-117.
17. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR,. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20: 329-352.
18. Jann MW, Ereshefsky L, Saklad SR, et al,. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106-109. (Pubitemid 15149502)
19. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM,. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986; 90: 468-470. (Pubitemid 17096773)